Research and develop a wide range of pharmaceutical products. Manufacture finished drugs and bulk pharmaceutical products. Now — the numbers.
This is an established company with proven profits.
No real growth (-2% a year).
If every debt were paid off today, $1.2B would still be left in the vault — a solid cushion for hard times.
The market pays 22.4× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 6 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
The stock trades 20% below its peak. The market has trimmed its expectations for the company.
There is $1.3B in the vault; even if every debt were paid off, $1.2B would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
It pays out $0.04 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 2% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.